What Is: Organoid

Organoids: The Science and Ethics of Mini-Organs
Image Credit: Scientific Frontline / AI generated

The "At a Glance" Summary

• Defining the Architecture: Unlike traditional cell cultures, organoids are 3D structures grown from pluripotent stem cells (iPSCs) or adult stem cells. They rely on the cells' intrinsic ability to self-organize, creating complex structures that mimic the lineage and spatial arrangement of an in vivo organ.
• The "Avatar" in the Lab: Organoids allow for Personalized Medicine. By growing an organoid from a specific patient's cells, researchers can test drug responses on a "digital twin" of that patient’s tumor or tissue, eliminating the guesswork of trial-and-error prescriptions.
• Bridge to Clinical Trials: Organoids serve as a critical bridge between the Petri dish and human clinical trials, potentially reducing the failure rate of new drugs and decreasing the reliance on animal testing models which often fail to predict human reactions.
• The Ethical Frontier: As cerebral organoids (mini-brains) become more complex, exhibiting brain waves similar to preterm infants, science faces a profound question: At what point does biological complexity become sentience?

Personalized Therapies for Rett Syndrome

Caption:Researchers grew advanced 3D cultures of human brain tissue from induced pluripotent stem cells to model specific Rett syndrome genetic mutations. Images from the research show organoids labeled to indicate cell types and electrical activity (via calcium imaging). Top: Purple staining highlights excitatory neurons, while white staining labels inhibitory neurons. Bottom left: Magenta shows jRGECO1a calcium imaging. Bottom right: Green highlights inhibitory neuron labeling with DLX-EGFP.
Image Credit: Tatsuya Osaki

Scientific Frontline: Extended "At a Glance" Summary: Personalized Treatments for Rett Syndrome

The Core Concept: A recent MIT study demonstrates that different mutations within the MECP2 gene, which causes Rett syndrome, result in distinct neurological abnormalities and require targeted, mutation-specific treatments rather than a universal therapeutic approach.

Key Distinction/Mechanism: Unlike previous research that simply knocked out the MECP2 gene entirely, this study utilized 3D human brain "organoids" (minibrains) derived from patient cells to model specific point mutations (R306C and V247X). This precise modeling revealed that each mutation causes unique structural, functional, and molecular deviations, such as differing neural network efficiencies and divergent gene expression profiles.

Major Frameworks/Components:

• 3D Brain Organoids: Advanced lab cultures grown from patient skin or blood cells, used to replicate a three-dimensional neural environment for accurately modeling genetic mutations.
• Three-Photon Microscopy: A high-resolution imaging technique used to visualize the structural layers of the 1-millimeter thick organoids and map the live calcium fluorescence activity of individual neurons.
• Single-Cell RNA Sequencing: An analytical method utilized to identify hundreds of variations in gene expression between the mutant organoids and control samples.
• Small-World Propensity (SWP): A measurable metric of neural network structure efficiency that decreased in R306C mutations but increased in V247X mutations.

Making lab-grown brain organoids ‘brainier

 Slices of mini–brain organoids with neural stem cells (red) and cortical neurons (green).
Credit: Hajime Ozaki, Watanabe lab/UCI

By using stem cells to grow miniature brain-like organs in the lab, scientists have opened a new avenue for studies of neurological development, disease and therapies that can’t be conducted in living people. But not all mini–brain organoids are created equal and getting them to precisely mimic the human brain tissues they’re modeling has been a persistent challenge.

“Right now, it’s like the Wild West because there is no standard method for generating mini–brain organoids,” said Bennett Novitch, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and the senior author of a new paper on the topic. “Every neuroscientist wants to make a brain organoid model of their favorite disease, and yet everyone’s organoids do not always look alike.”

In fact, because there is no common protocol for their production and a lack of quality-control guidelines, organoids can vary from lab to lab — and even from batch to batch — which means that a finding made in one organoid may not hold true in another.

“If my lab and another lab down the hall were to conduct drug screens using mini–brain organoid models of the same disorder, we could still get different results,” said Momoko Watanabe, the new paper’s first author and an assistant professor of anatomy and neurobiology at UC Irvine. “We won’t know whose findings are correct because the differences we’re seeing could be reflections of how our models differ rather than reflections of the disease.”

New Sensors Lower the Cost of Studying Genetic Disorders

Photo Credit: Navya Mishra.

Scientific Frontline: Extended "At a Glance" Summary: CAMEO Sensor Technology for Cerebral Organoids

The Core Concept: CAMEO (Conformal Array for Monitoring Electrophysiology of Organoids) is a low-cost, scalable sensor platform designed to monitor electrical activity within human cerebral organoids.

Key Distinction/Mechanism: Unlike traditional, expensive microelectrode arrays that rely on costly materials, CAMEO utilizes 12 flexible carbon nanotube strands arranged in a basket-like structure. This design suspends the organoid and detects low-amplitude electrophysiological signals without the need for specialized workflows or expensive gold electrodes.

Major Frameworks/Components: 

• Human Cerebral Organoids: Millimeter-sized tissues cultured from stem cells that replicate the complexity and specific cell types of human brain regions.
• Carbon Nanotube Microelectrode Arrays (MEAs): Highly sensitive, flexible 3D electrodes capable of recording extracellular electrophysiological activity.
• High-Throughput Processing: A scalable diagnostic approach that allows for simultaneous, multi-sample data collection in standard cell culture plates.

Paralysis treatment heals lab-grown human spinal cord organoids

Fluorescent micrographs showing increased neurite outgrowth from a human spinal cord organoid treated with fast-moving “dancing molecules” (left) compared to one treated with slow-moving molecules (right) containing the same bioactive signals
Image Credit: Samuel I. Stupp/Northwestern University

Scientific Frontline: Extended "At a Glance" Summary

The Core Concept: Lab-grown human spinal cord organoids are miniature, three-dimensional tissue models derived from stem cells that mimic the complex structure and function of the human spinal cord to simulate injuries and test regenerative treatments.

Key Distinction/Mechanism: Unlike previous models, these organoids incorporate microglia—the central nervous system's immune cells—allowing researchers to accurately replicate the inflammatory response and glial scarring seen in human spinal cord injuries. The "dancing molecules" therapy creates a nanofiber scaffold where rapidly moving molecules effectively engage cellular receptors to trigger neurite growth and reverse paralysis, a mechanism significantly more effective than therapies using static molecules.

Major Frameworks/Components:

• Induced Pluripotent Stem Cells (iPSCs): The source material for growing the organoids, allowing for patient-specific tissue generation.
• Supramolecular Therapeutic Peptides (STPs): The chemical basis of the "dancing molecules" that assemble into nanofibers.
• Microglia Integration: The inclusion of immune cells to create a "pseudo-organ" that mimics natural inflammatory responses.
• Glial Scarring: A physical barrier to nerve regeneration that the therapy successfully diminished in trials.

Branch of Science: Regenerative Medicine, Nanotechnology, Neuroscience, and Bioengineering.

Future Application: The technology paves the way for personalized medicine, where a patient's own stem cells could be used to grow implantable tissues that avoid immune rejection. It also offers a platform to test treatments for chronic, long-term spinal cord injuries and other neurodegenerative conditions.

Why It Matters: This advancement bridges the gap between animal studies and clinical trials, providing a highly accurate human model for spinal cord injury. It validates a promising therapy that has earned Orphan Drug Designation from the FDA, offering renewed hope for restoring function in paralyzed patients.

Brain research with organoids

Section of an electroporated brain organoid of a common marmoset. Green: electroporated cells that glow green due to the green fluorescent protein; magenta: neurons; gray: nuclei.
Photo Credit: Lidiia Tynianskaia

Scientists at the German Primate Center develop effective method to genetically modify brain organoids

Primates are among the most intelligent creatures with distinct cognitive abilities. Their brains are relatively large in relation to their body stature and have a complex structure. However, how the brain has developed over the course of evolution and which genes are responsible for the high cognitive abilities is still largely unclear. The better our understanding of the role of genes in brain development, the more likely it will be that we will be able to develop treatments for serious brain diseases. 

Researchers are approaching these questions by knocking out or activating individual genes and thus drawing conclusions about their role in brain development. To avoid animal experiments as far as possible, brain organoids are used as an alternative. These three-dimensional cell structures, which are only a few millimeters in size, reflect different stages of brain development and can be genetically modified. However, such modifications are usually very complex, lengthy and costly. Researchers at the German Primate Center (DPZ) – Leibniz Institute for Primate Research in Göttingen have now succeeded in genetically manipulating brain organoids quickly and effectively. 

Mini-Livers on a Chip

Researchers at Gladstone Institutes designed a new platform for studying how the human immune system responds to hepatitis C infection by combining microfluidic technology with liver organoids. Credit: Gladstone Institutes

A vaccine for hepatitis C has eluded scientists for more than 30 years, for several reasons. For one, the virus that causes the disease comes in many genetic forms, complicating the creation of a widely effective vaccine. For another, studying hepatitis C has been difficult because options in animals are limited and lab methods using infected cells have not adequately reflected the real-life dynamics of infection.

Now, researchers at Gladstone Institutes have developed a new platform for studying how the human immune system responds to hepatitis C infection. The method, presented in the scientific journal Open Biology, marries microfluidic technology (which allows scientists to precisely manipulate fluid at a microscopic scale) with liver organoids (three-dimensional cell clusters that mimic the biology of real human livers).

“The 3D structure and cellular composition of liver organoids allows us to study viral entry and replication in a highly relevant physiological manner,” says Gladstone Senior Investigator Todd McDevitt, PhD, a senior author of the new study.

“Our approach enables a more controlled and accurate investigation into the immune response to hepatitis C infection,” says Melanie Ott, MD, PhD, director of the Gladstone Institute of Virology and another senior author of the study. “We hope our method will accelerate the discovery of a much-needed vaccine.”

The gene to which we owe our big brain

A section of a brain organoid made from stem cells of a human. In magenta are actively proliferating brain stem cells, in yellow a subset of brain stem cells.
Photo Credit: Jan Fischer

ARHGAP11B - this complex name is given to a gene that is unique to humans and plays an essential role in the development of the neocortex. The neocortex is the part of the brain to which we owe our high mental abilities. A team of researchers from the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, the Max Planck Institute for Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, and the Hector Institute for Translational Brain Research (HITBR) in Mannheim has investigated the importance of ARHGAP11B in neocortex development during human evolution. 

To do this, the team introduced for the first time a gene that exists only in humans into laboratory-grown brain organoids from our closest living relatives, chimpanzees. In the chimpanzee brain organoid, the ARHGAP11B gene led to an increase in brain stem cells relevant to brain growth and an increase in those neurons that play a critical role in the extraordinary mental abilities of humans. If, on the other hand, the ARHGAP11B gene was switched off in human brain organoids, the quantity of these brain stem cells fell to the level of a chimpanzee. Thus, the research team was able to show that the ARGHAP11B gene played a crucial role in the evolution of the brain from our ancestors to modern humans.

Fine-tuning 3D lab-grown mini tumors to help predict how patients respond to cancer therapies

The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail.
Image Credit: Soragni Lab.

Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a new method to bio-print miniature tumor organoids that are designed to mimic the function and architecture of real tumors. The improved process allows researchers to use an advanced imaging method to study and analyze individual organoids in great detail, which can help researchers identify personalized treatments for people with rare or hard-to-treat cancers.

The method is described in the journal Nature Communications.

“Tumor organoids have become fundamental tools to investigate tumor biology and highlight drug sensitivities of individual patients,” said Alice Soragni, PhD, an assistant professor in the department of Orthopedic Surgery at the David Geffen School of Medicine at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center. “However, we still need better ways to anticipate if resistance could be arising in a small population of cells, which we may not detect using conventional screening approaches. This is truly important, particularly as organoid-based drug predictions are starting to be leveraged clinically.”

Engineers grow pancreatic organoids

MIT and Cancer Research UK Manchester Institute researchers have
developed a synthetic gel that can be used to grow tiny
pancreatic organoids, seen here, from human pancreatic cells.
Credits: Courtesy of the researchers.

MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas, using either healthy or cancerous pancreatic cells. Their new models could help researchers develop and test potential drugs for pancreatic cancer, which is currently one of the most difficult types of cancer to treat.

Using a specialized gel that mimics the extracellular environment surrounding the pancreas, the researchers were able to grow pancreatic “organoids,” allowing them to study the important interactions between pancreatic tumors and their environment. Unlike some of the gels now used to grow tissue, the new MIT gel is completely synthetic, easy to assemble and can be produced with a consistent composition every time.

Lab-grown ‘mini brains’ hint at treatments for neurodegenerative diseases

Mini brain organoids showing cortical-like structures 
Credit: Andras Lakatos

A common form of motor neuron disease, amyotrophic lateral sclerosis, often overlaps with frontotemporal dementia (ALS/FTD) and can affect younger people, occurring mostly after the age of 40-45. These conditions cause devastating symptoms of muscle weakness with changes in memory, behavior and personality. Being able to grow small organ-like models (organoids) of the brain allows the researchers to understand what happens at the earliest stages of ALS/FTD, long before symptoms begin to emerge, and to screen for potential drugs.

In general, organoids, often referred to as ‘mini organs’, are being used increasingly to model human biology and disease. At the University of Cambridge alone, researchers use them to repair damaged livers, SARS-CoV-2 infection of the lungs and model the early stages of pregnancy, among many other areas of research.

Typically, researchers take cells from a patient’s skin and reprogram the cells back to their stem cell stage – a very early stage of development at which they have the potential to develop into most types of cell. These can then be grown in culture as 3D clusters that mimic particular elements of an organ. As many diseases are caused in part by defects in our DNA, this technique allows researchers to see how cellular changes – often associated with these genetic mutations – lead to disease.

Artificial intelligence supports the search for new therapies

The 3D model of the midbrain showed improved growth and lower lactate release with talarozole and sertaconazole.
Image Credit: © HHU / Carmen Menacho 

Scientific Frontline: Extended "At a Glance" Summary: AI-Assisted Therapy Discovery for Leigh Syndrome

The Core Concept: Researchers have combined 3D brain organoid models and artificial intelligence to identify potential existing drugs for repurposing to treat Leigh Syndrome, a rare and fatal mitochondrial disease.

Key Distinction/Mechanism: Unlike traditional drug discovery, this approach utilizes lab-grown pluripotent stem cells developed into 3D brain organoids that mimic the genetic variations of the disease, coupled with a deep-learning algorithm to rapidly screen and identify promising existing medications.

Major Frameworks/Components:

• Pluripotent Stem Cells: Patient cells cultivated and differentiated into specialized biological matter.
• 3D Brain Organoids: Laboratory-generated 3D models imitating human brain tissue structure and the specific genetic mutation triggering Leigh Syndrome.
• Deep Learning AI: An algorithm designed to optimize the drug screening process and predict therapeutic candidates.
• Drug Repurposing: Evaluating pre-existing, approved medications (such as talarozole and sertaconazole) for new clinical applications to bypass lengthy initial development phases.

A new at­las il­lus­trates how the hu­man ret­ina is de­vel­op­ing.

De­tail of a cross-​section of a ret­inal or­ganoid. Dif­fer­ent tis­sue struc­tures are made vis­ible with dif­fer­ent colors.
Pho­to­ Credit: Wahle et al. Nature Bi­o­tech­no­logy 2023

What cell types are found in which hu­man tis­sue, and where? Which genes are act­ive in the in­di­vidual cells, and which pro­teins are found there? An­swers to these ques­tions and more are to be provided by a specialized at­las – in par­tic­u­lar how the dif­fer­ent tis­sues form dur­ing em­bryonic de­vel­op­ment and what causes dis­eases. In cre­at­ing this at­las, re­search­ers aim to map not only tis­sue dir­ectly isol­ated from hu­mans, but also struc­tures called or­ganoids. These are three-​dimensional clumps of tis­sue that are cul­tiv­ated in the labor­at­ory and de­velop in a way sim­ilar to hu­man or­gans, but on a small scale.

“The ad­vant­age of or­ganoids is that we can in­ter­vene in their de­vel­op­ment and test act­ive sub­stances on them, which al­lows us to learn more about healthy tis­sue as well as dis­eases,” ex­plains Bar­bara Treut­lein, Pro­fessor of Quant­it­at­ive De­vel­op­mental Bio­logy at the De­part­ment of Biosys­tems Sci­ence and En­gin­eer­ing at ETH Zurich in Basel.

To help pro­duce such an at­las, Treut­lein, to­gether with re­search­ers from the Uni­ver­sit­ies of Zurich and Basel, has now de­veloped an ap­proach to gather and com­pile a great deal of in­form­a­tion about or­ganoids and their de­vel­op­ment. The re­search team ap­plied this ap­proach to the or­ganoids of the hu­man ret­ina, which they de­rived from stem cells.

Not unique to humans but uniquely human: researchers identify factor involved in brain expansion in humans

A microscopy image of a human brain organoid.
Image Credit: © Janine Hoffmann

What makes us human? According to neurobiologists it is our neocortex. This outer layer of the brain is rich in neurons and lets us do abstract thinking, create art, and speak complex languages. An international team led by Dr. Mareike Albert at the Center for Regenerative Therapies Dresden (CRTD) of TUD Dresden University of Technology has identified a new factor that might have contributed to neocortex expansion in humans. The results were published in the EMBO Journal.

The neocortex is the characteristic folded outer layer of the brain that resembles a walnut. It is responsible for higher cognitive functions such as abstract thinking, art, and language. “The neocortex is the most recently evolved part of the brain,” says Dr. Mareike Albert, research group leader at the CRTD. “All mammals have a neocortex, but it varies in size and complexity. Human and primate neocortices have folds while, for example, mice have a completely smooth neocortex, without any creases.”

The folds characteristic of the human brain increases the surface area of the neocortex. The human neocortex has a greater number of neurons that support complex cognitive functions.

The molecular mechanisms driving neocortex evolution are still largely unknown. “Which genes are responsible for inter-species differences in neocortex size? What factors have contributed to brain expansion in humans? Answering these questions is crucial to understanding human brain development and potentially addressing mental health disorders,” explains Dr. Albert.

Model study on the antiepileptic drug valproate: Influence on early brain development

Brain research in the Petri dish: Organoids can be used to understand disease processes.
Photo Credit: Amadeus Bramsiepe, KIT

Scientific Frontline: Extended "At a Glance" Summary: Valproate and Early Brain Development

The Core Concept: A recent study utilizes 3D human brain organoids to investigate how the widely used antiepileptic drug valproate disrupts early fetal brain development and contributes to neurodevelopmental disorders.

Key Distinction/Mechanism: Researchers discovered that valproate alters the extracellular microenvironment, making it stiffer. This physical and structural change inhibits cell proliferation, disrupts key developmental zones, and impairs the crucial signaling required for progenitor cells to properly mature into functional nerve cells.

Major Frameworks/Components: 

• Human Brain Organoids: 3D tissue structures grown in the laboratory from stem cells, used to simulate and observe human prenatal brain development over a 30-day drug exposure period.
• Extracellular Environment Analysis: Investigating how the structural and mechanical stiffening of the space surrounding cells impairs central neural communication.
• Multiomics Profiling: Evaluating the valproate-induced alterations simultaneously across tissue, cellular, and molecular levels.

Scientists discover potential treatment approaches for polycystic kidney disease

cientists would like to know how cysts form in polycystic kidney disease (PKD). Here, they compared two 3-D mini-kidney models. On the left, a model shows a mini kidney with a gene mutation that causes cysts to form. On the right, researchers used gene editing to correct a gene mutation, preventing the development of cysts.
Image Credit: Vishy, et al., Cell Stem Cell 2024

Researchers have shown that dangerous cysts, which form over time in polycystic kidney disease (PKD), can be prevented by a single normal copy of a defective gene. This means the potential exists that scientists could one day tailor a gene therapy to treat the disease. They also discovered that a type of drug, known as a glycoside, can sidestep the effects of the defective gene in PKD. The discoveries could set the stage for new therapeutic approaches to treating PKD, which affects millions worldwide. The study, partially funded by the National Institutes of Health (NIH), is published in Cell Stem Cell.

Scientists used gene editing and 3-D human cell models known as organoids to study the genetics of PKD, which is a life-threatening, inherited kidney disorder in which a gene defect causes microscopic tubes in the kidneys to expand like water balloons, forming cysts over decades. The cysts can crowd out healthy tissue, leading to kidney function problems and kidney failure. Most people with PKD are born with one healthy gene copy and one defective gene copy in their cells.

“Human PKD has been so difficult to study because cysts take years and decades to form,” said senior study author Benjamin Freedman, Ph.D., at the University of Washington, Seattle. “This new platform finally gives us a model to study the genetics of the disease and hopefully start to provide answers to the millions affected by this disease.”

How Did Humans Develop Sharp Vision? Lab-Grown Retinas Show Likely Answer

Image representation
Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Retina Organoids & Human Vision

The Core Concept: Retina organoids are lab-grown, three-dimensional clusters of retinal tissue derived from fetal cells that replicate the developmental processes of the human eye in a controlled environment.

Key Distinction/Mechanism: Unlike previous models which suggested blue cone cells physically migrated out of the central retina (foveola), these organoids revealed that cells undergo a conversion process. The mechanism is two-fold: retinoic acid (a vitamin A derivative) breaks down to limit the initial creation of blue cones, and thyroid hormones subsequently signal the remaining blue cones to transform into red and green cones, establishing the specialized pattern required for sharp daytime vision.

Origin/History: The findings were published in the Proceedings of the National Academy of Sciences around February 18, 2026. This research challenges a prevailing 30-year-old biological theory regarding how the eye distributes light-sensing cells during development.

Major Frameworks/Components:

• Organoid Technology: The cultivation of "mini-retinas" in petri dishes to observe long-term developmental timelines.
• The Foveola: The specific central region of the retina responsible for 50% of visual perception and high-acuity vision.
• Cell Fate Specification: The biological programming that determines whether a photoreceptor becomes a blue, green, or red cone.
• Hormonal Signaling: The specific interplay between retinoic acid and thyroid hormones in dictating cell identity.

‘Live’ brain models used in hunt for Alzheimer’s treatment

Alzheimer plaques in human stem cell derived neurons

Studying tiny ‘live’ models of the human brain has helped researchers understand its ageing and find a key to potential treatments for Alzheimer’s and other neurodegenerative diseases.

University of Queensland scientists have found different cellular mechanisms that can either accelerate or reduce brain cell deterioration.

Professor Ernst Wolvetang studied organoids, models that closely mimic the human brain, at UQ’s Australian Institute for Bioengineering and Nanotechnology.

“We have found that human brain organoids can be used to study the molecular mechanisms that drive brain ageing processes,” Professor Wolvetang said.

“This opens the way for testing many molecules that could become potential therapeutic drugs for a host of neurodegenerative diseases.”

Using the organoids, Professor Wolvetang and Dr Julio Aguado found DNA leakage accelerated ageing in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T).

In another research project, Professor Wolvetang and Dr Mohammed Shaker found that increasing levels of the ‘anti-ageing’ protein klotho reduced the deterioration in brain cells associated with age and dementia.

Lab-grown retina gives gene change clue to rare childhood eye condition

retinal organoid
Image Credit: Courtesy of University of Manchester

Scientific Frontline: Extended "At a Glance" Summary: YAP1 Gene Variations and Ocular Coloboma

The Core Concept: Ocular coloboma is a congenital eye defect that occurs when the optic fissure fails to close properly during early development. Recent research utilizing lab-grown, miniature human retinas—known as retinal organoids—has identified how mutations in a specific growth-controlling protein contribute to this condition.

Key Distinction/Mechanism: The biological mechanism centers on the YAP1 protein, which functions as a cellular switch directing organ formation and tissue health. Disruptions or genetic variants in YAP1 reduce the activity of genes necessary for early retinal cells to grow and maintain their identity. Consequently, these cells develop too slowly, resulting in eye formation failure. The exact location of the mutation on the gene dictates the severity of the YAP1 functional disruption, explaining the wide variance of symptoms among patients carrying changes in the same gene.

Major Frameworks/Components: 

• Retinal Organoids: Utilizing stem-cell models to cultivate miniature, lab-grown versions of the developing human retina for in-vitro analysis.
• YAP1 Protein Regulation: Investigating the biochemical pathway where YAP1 directs cellular growth, differentiation, and survival based on received signals.
• Computational and Experimental Modeling: Combining computer modeling with experimental data to map the domain-specific impacts of various YAP1 mutations.
• Alternative Research Models: Employing human organoids as an ethical framework to reduce, refine, and replace the use of animal models in developmental biology.

Did Lead Limit Brain and Language Development in Neanderthals and Other Extinct Hominids?

UC San Diego researchers have found high levels of lead in the teeth of both Neanderthals (left) and modern humans (right). However, a gene mutation may have protected modern human brains, allowing language to flourish.
Photo Credit: Kyle Dykes/UC San Diego Health Sciences

Ancient human relatives were exposed to lead up to two million years ago, according to a new study. However, a gene mutation may have protected modern human brains, allowing language to flourish.

What set the modern human brain apart from our now extinct relatives like Neanderthals? A new study by University of California San Diego School of Medicine and an international team of researchers reveals that ancient hominids — including early humans and great apes — were exposed to lead earlier than previously thought, up to two million years before modern humans began mining the metal. This exposure may have shaped the evolution of hominid brains, limiting language and social development in all but modern humans due to a protective genetic variant that only we carry. The study was published in Science Advances.

The researchers analyzed fossilized teeth from 51 hominids across Africa, Asia and Europe, including modern and archaic humans such as Neanderthals, ancient human ancestors like Australopithecus africanus, and extinct great apes such as Gigantopithecus blacki.